AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
NRx Pharmaceuticals Amends IND to Advance NRX-101 for Depression Treatment with TMS
ByAinvest
Wednesday, Dec 3, 2025 2:41 pm ET1min read
NRx Pharmaceuticals has amended its Investigational New Drug filing for NRX-101 to include its use in combination with Transcranial Magnetic Stimulation (TMS) for depression treatment. The update follows evidence showing NRX-101 may significantly enhance TMS outcomes, with published studies showing more than two-fold improvements in symptom reduction and clinical response rates exceeding 80%. The Company aims to validate these findings in a well-controlled trial and is in partnership discussions with TMS device manufacturers.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet